1. Home
  2. NNBR vs TLPH Comparison

NNBR vs TLPH Comparison

Compare NNBR & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NN Inc.

NNBR

NN Inc.

HOLD

Current Price

$1.24

Market Cap

81.8M

Sector

Industrials

ML Signal

HOLD

TLPH

Talphera Inc.

HOLD

Current Price

$0.84

Market Cap

37.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NNBR
TLPH
Founded
1980
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.8M
37.9M
IPO Year
1996
2010

Fundamental Metrics

Financial Performance
Metric
NNBR
TLPH
Price
$1.24
$0.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$3.00
$6.00
AVG Volume (30 Days)
212.4K
204.0K
Earning Date
06-12-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
3.60
N/A
EPS
N/A
N/A
Revenue
$770,657,000.00
$2,151,000.00
Revenue This Year
$8.27
N/A
Revenue Next Year
$5.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$0.38
52 Week High
$2.67
$1.57

Technical Indicators

Market Signals
Indicator
NNBR
TLPH
Relative Strength Index (RSI) 30.95 43.10
Support Level $1.20 $0.76
Resistance Level $1.43 $0.88
Average True Range (ATR) 0.09 0.05
MACD -0.03 -0.00
Stochastic Oscillator 6.17 34.89

Price Performance

Historical Comparison
NNBR
TLPH

About NNBR NN Inc.

NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets.

About TLPH Talphera Inc.

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Share on Social Networks: